PMID- 26899537
OWN - NLM
STAT- MEDLINE
DCOM- 20170117
LR  - 20220410
IS  - 1179-187X (Electronic)
IS  - 1175-3277 (Linking)
VI  - 16
IP  - 3
DP  - 2016 Jun
TI  - Efficacy of Short-Term Statin Treatment for the Prevention of Contrast-Induced 
      Acute Kidney Injury in Patients Undergoing Coronary Angiography/Percutaneous 
      Coronary Intervention: A Meta-Analysis of 21 Randomized Controlled Trials.
PG  - 201-19
LID - 10.1007/s40256-016-0164-5 [doi]
AB  - BACKGROUND: The results of previous studies have been contradictory in terms of 
      the efficacy of statin treatment in preventing contrast-induced acute kidney 
      injury (CI-AKI) and clinical adverse events (AEs). OBJECTIVE: This meta-analysis 
      was undertaken to assess the role of short-term statin treatment in the 
      prevention of CI-AKI and clinical AEs. METHODS: We searched the Cochrane Library, 
      EMBASE, and PubMed databases for randomized controlled trials (RCTs) with the 
      development of CI-AKI as a primary outcome. Secondary outcomes were the 
      post-procedural serum creatinine (SCr) level, estimated glomerular filtration 
      rate (eGFR), and development of AEs. We also performed prespecified subgroup 
      analyses. RESULTS: A total of 21 RCTs involving 7746 patients were included. 
      Short-term statin treatment significantly reduced the risk of CI-AKI [risk ratio 
      (RR) 0.57; 95 % confident interval (CI) 0.47-0.69; p < 0.00001) and was 
      associated with a lower post-procedural SCr level and a higher eGFR. High-dose 
      statins resulted in a lower incidence of CI-AKI than the lower-dose statins. In 
      addition, the benefit was seen across various subgroups for patients at risk of 
      CI-AKI, statin-naive patients, and East Asians, regardless of statin type, 
      definition of CI-AKI, use of N-acetylcysteine (NAC) and hydration, and osmolality 
      of contrast. However, there was no significant difference between the two groups 
      in terms of the incidence of AEs. CONCLUSIONS: The meta-analysis suggests that 
      short-term statin treatment can effectively prevent CI-AKI, and the benefit is 
      also observed in high-risk patients, statin-naive patients, and an East Asian 
      population. However, the effect of simvastatin for the prevention of CI-AKI, of 
      statins for the prevention of AEs, and whether high-dose statins have a better 
      effect than lower-dose statins are all still uncertain.
FAU - Li, Haixia
AU  - Li H
AD  - Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 
      Liaoning, China.
FAU - Wang, Cailian
AU  - Wang C
AD  - Department of Cardiology, General Hospital of Shenyang Military Area, Shenhe 
      District, Shenyang, Liaoning, China.
FAU - Liu, Chuanzhi
AU  - Liu C
AD  - Department of Nephrology, General Hospital of Shenyang Military Area, Shenhe 
      District, Shenyang, Liaoning, China.
FAU - Li, Ruifei
AU  - Li R
AD  - Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 
      Liaoning, China.
FAU - Zou, Meijuan
AU  - Zou M
AD  - Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 
      Liaoning, China.
FAU - Cheng, Gang
AU  - Cheng G
AD  - Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 
      Liaoning, China. chenggang63@hotmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Contrast Media)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
SB  - IM
MH  - Acute Kidney Injury/chemically induced/epidemiology/*prevention & control
MH  - Contrast Media/*adverse effects
MH  - Coronary Angiography/*adverse effects
MH  - *Evidence-Based Medicine
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Iatrogenic Disease/epidemiology/prevention & control
MH  - Percutaneous Coronary Intervention/*adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Risk
EDAT- 2016/02/24 06:00
MHDA- 2017/01/18 06:00
CRDT- 2016/02/23 06:00
PHST- 2016/02/23 06:00 [entrez]
PHST- 2016/02/24 06:00 [pubmed]
PHST- 2017/01/18 06:00 [medline]
AID - 10.1007/s40256-016-0164-5 [pii]
AID - 10.1007/s40256-016-0164-5 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2016 Jun;16(3):201-19. doi: 10.1007/s40256-016-0164-5.